Business Description
Initiator Pharma AS
ISIN : DK0060775872
Total Employee Number:
1Compare
Compare
Traded in other countries / regions
INIT.Sweden IPO Date
2017-03-16Description
Initiator Pharma AS is a Danish clinical-stage life science company developing drugs that target key unmet medical needs within the central and peripheral nervous system. Its pipeline consists of three clinical programs: IP2018 and pudafensine for the treatment of erectile dysfunction of psychogenic and organic origin, respectively.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.63 | |||||
Equity-to-Asset | 0.68 | |||||
Debt-to-Equity | 0.42 | |||||
Debt-to-EBITDA | -0.28 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 32.6 | |||||
3-Year EPS without NRI Growth Rate | 35.3 | |||||
3-Year FCF Growth Rate | 25.4 | |||||
3-Year Book Growth Rate | -13.1 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 12.62 | |||||
9-Day RSI | 25.03 | |||||
14-Day RSI | 31.71 | |||||
3-1 Month Momentum % | -19.51 | |||||
6-1 Month Momentum % | -12.87 | |||||
12-1 Month Momentum % | -25.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 23.53 | |||||
Quick Ratio | 23.53 | |||||
Cash Ratio | 17.5 | |||||
Days Payable | 23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -9.3 | |||||
Shareholder Yield % | -23.12 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -111.91 | |||||
ROA % | -90.5 | |||||
ROIC % | -439.18 | |||||
3-Year ROIIC % | -2369.55 | |||||
ROC (Joel Greenblatt) % | -657.99 | |||||
ROCE % | -115.58 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 6.54 | |||||
Price-to-Tangible-Book | 6.53 | |||||
EV-to-EBIT | -3.92 | |||||
EV-to-Forward-EBIT | 8.07 | |||||
EV-to-EBITDA | -3.92 | |||||
EV-to-Forward-EBITDA | 8.07 | |||||
EV-to-Forward-Revenue | 3.4 | |||||
EV-to-FCF | -4.15 | |||||
| Price-to-Net-Current-Asset-Value | 6.53 | |||||
| Price-to-Net-Cash | 10.78 | |||||
Earnings Yield (Greenblatt) % | -25.52 | |||||
FCF Yield % | -23.16 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Initiator Pharma AS Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -0.494 | ||
| Beta | -0.0886 | ||
| 3-Year Sharpe Ratio | -0.69 | ||
| 3-Year Sortino Ratio | -0.82 | ||
| Volatility % | 29.75 | ||
| 14-Day RSI | 31.71 | ||
| 14-Day ATR (kr) | 0.201966 | ||
| 20-Day SMA (kr) | 2.7495 | ||
| 12-1 Month Momentum % | -25.63 | ||
| 52-Week Range (kr) | 2.41 - 4.07 | ||
| Shares Outstanding (Mil) | 68.45 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Initiator Pharma AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Initiator Pharma AS Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-20 | In 129 days | ||
| Second quarter earnings results for 2026 | 2026-08-21 | In 38 days | ||
| General meeting for 2026 | 2026-05-29 10:00 | 2.90 (-0.68%) | ||
| First quarter earnings results for 2026 | 2026-05-08 | 3.37 (+1.51%) | ||
| Annual report for 2025 | 2026-04-28 | 3.13 (-1.88%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-20 | 3.56 (+9.20%) | ||
| Third quarter earnings results for 2025 | 2025-11-21 | 2.80 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-22 | 3.45 (+1.47%) | ||
| General meeting for 2025 | 2025-05-23 10:00 | 3.71 (+1.09%) | ||
| First quarter earnings results for 2025 | 2025-05-09 | 6.40 (+5.61%) |
Show
Entries
Initiator Pharma AS Frequently Asked Questions
What is Initiator Pharma AS(OSTO:INIT)'s stock price today?
The current price of OSTO:INIT is kr2.48. The 52 week high of OSTO:INIT is kr4.07 and 52 week low is kr2.41.
When is next earnings date of Initiator Pharma AS(OSTO:INIT)?
The next earnings date of Initiator Pharma AS(OSTO:INIT) is 2026-08-21.
Does Initiator Pharma AS(OSTO:INIT) pay dividends? If so, how much?
Initiator Pharma AS(OSTO:INIT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Initiator Pharma AS
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers